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ABSTRACT
Since the 1960s, the incidence of malignant mesothe-
lioma in Canada has increased dramatically because
of work-related asbestos exposures. Treatment options
are limited. Although chemotherapy is now an accepted
standard in the management of advanced disease, un-
certainty surrounds the roles of radical surgery and ra-
diation. In March 2007, a symposium was held in Van-
couver, B.C., to review the current approach to malig-
nant mesothelioma in Canada and to discuss develop-
ment of a national clinical research strategy.
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1. INTRODUCTION
Since the 1960s, industrial exposure to asbestos has
led to a dramatic rise in the number of cases of ma-
lignant mesothelioma 1,2. In developed countries, the
incidence of mesothelioma is expected to plateau as
a result of the introduction of safety guidelines in the
workplace since the 1970s 3,4. Bans on asbestos are
also anticipated to have a positive effect in countries
that have implemented such restrictions 5. However,
global production of asbestos has not changed since
the late 1990s because of exports to emerging mar-
kets. Inadequate management practices and unregu-
lated handling of asbestos in developing countries are
expected to sustain the increase in worldwide inci-
dence indefinitely 1.
In Canada, a nationwide audit of all “fatal malig-
nant mesothelial tumors” from 1959 to mid-1968 iden-
tified a total of 165 cases 6. The most recent data avail-
able from the National Cancer Institute of Canada
(NCIC) indicate that 391 new cases of mesothelioma
were diagnosed in 2003, with 343 deaths from mes-
othelioma occurring that year 7. Mesothelioma is likely
a significant contributor to asbestos-related deaths in
Canada, in 2005 accounting for 61% of deaths from
occupational diseases and for 31% of all workplace
fatalities 8.
The most notable advance in the management of
mesothelioma in recent years has been the establish-
ment of platinum-based combination chemotherapy as
a standard of care in unresectable disease 9. However,
the survival benefit is modest, and uncertainty remains
about the roles of radical surgery and radiotherapy 10,11.
Further progress in the treatment of mesothelioma is
needed. To encourage a national dialogue, a sympo-
sium was held in Vancouver, B.C., on March 24 and
25, 2007, sponsored by the NCIC Clinical Trials Group
(CTG) and the Canadian Institutes of Health Research–
Institute of Cancer Research. Current standards in
management of mesothelioma were reviewed, and di-
rections for clinical research in Canada were discussed.
2. SUMMARY OF PRESENTATIONS
2.1 Histology and Molecular Markers
The Classification for Tumours of the Lung, Pleura,
Thymus and Heart from the World Health Organiza-
tion categorizes tumours of the pleura into mesothe-
lial tumours and lymphoproliferative disorders 12.
Diffuse mesotheliomas comprise the main subdivi-
sion of malignant mesothelial tumours, and these are
further subcategorized according to histology as epi-
thelial, spindled (sarcomatoid), or biphasic. The In-
ternational Classification of Diseases for Oncology
includes corresponding codes for those histologies,
together with a code for malignant mesothelioma not
otherwise specified 13.
The histologic characteristics of most mesothelioma
cells include uniform, bland-appearing, round nuclei
with finely dispersed chromatin and a single nucleo-
lus. Occasional cases show greater pleomorphism. A
key feature of malignant mesothelial cell proliferation
is invasion into adjacent tissue, particularly adiposeLEE et al.
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tissue. Because of an inability to provide this detail,
cytology is often inadequate, and biopsy specimens are
preferred 14. Still, several histologic features of mes-
othelioma are shared by other malignancies, which
means that making the diagnosis can be challenging.
Routine pathology examination of suspected
cases includes immunohistochemistry, although no
single tumour marker is considered pathognomonic
15. Table I lists typical marker patterns for epithelial
mesothelioma. In practice, a diagnosis of mesothe-
lioma requires two positive markers and two nega-
tive markers. In general, immunostains are less help-
ful in distinguishing sarcomatoid mesothelioma from
other sarcomatous neoplasms, although most sarco-
matoid mesotheliomas stain positive for broad-spec-
trum cytokeratin cocktail 16.
Ultrastructural findings can be diagnostic 17. Long
microvilli on the cell surface are typical of mesothe-
lioma, and electron microscopy is also of value if it
can rule out the diagnosis by revealing features of
other malignancies.
Molecular characterization of mesothelioma is at
a relatively early stage of development. A number of
chromosomal abnormalities have been associated with
the disease and its prognosis 12. Inactivation of the
CDKN2A/ARF locus on the short arm of chromosome
9 commonly occurs 18,19. Microarray profiling has also
suggested gene patterns associated with prognosis, but
validation of results to date are required, and the utility
of the observed patterns in a diagnostic algorithm re-
mains uncertain 20.
Perhaps of more immediate clinical interest are stu-
dies of serum markers such as mesothelin and osteo-
pontin 21,22. Although not specific to mesothelioma, these
molecules appear to be sensitive markers of the dis-
ease, and ongoing studies will better define their role in
screening for and diagnosing mesothelioma.
2.2 Diagnostic and Functional Imaging
The classic anatomic appearance of malignant pleural
mesothelioma (MPM) is a tumour rind that follows the
contour of the inner chest wall to encircle the lung, in
association with a pleural effusion that can be large or
small. The pleural thickening is often nodular and in-
volves the mediastinal pleura and fissures. The thick-
ening can be diffuse or focal and associated with ipsi-
lateral volume contraction or expansion. Rarely, MPM
will present as a spontaneous pneumothorax without
appreciable pleural thickening on computed tomog-
raphy (CT), or as bilateral disease.
Chest radiography has major limitations when as-
sessing pleural-based disease. Its limited contrast reso-
lution as compared with CT makes areas of solid tu-
mour difficult to distinguish from loculated pleural ef-
fusions. The primary imaging modality used to assess
the pleura is CT, and criteria have been established to
aid in the distinction between benign and malignant
pleural processes in CT imaging 23. Although those
criteria are not specific to MPM, CT is readily relied on
to evaluate and document the extent of disease 24,25.
In assessing response to treatment, the standard
Response Evaluation Criteria in Solid Tumors (RECIST)
are difficult to apply, because interpreting the maximum
diameter of pleural-based tumour is highly observer-
dependent and may not accurately reflect the status
of the disease 26. Modified response criteria (modi-
fied RECIST) focusing on measuring tumour thickness
have been developed that appear better suited to deal-
ing with the measurement problems created by a tu-
mour rind 27,28. More refined assessments of tumour
bulk can be obtained using CT imaging and a compu-
ter interface to map areas of tumour thickness either
by hand or by computer 29. However, the various
methods employed produced significant variability,
and the technique requires further development. The
appropriateness of using, in routine practice, any tu-
mour response criteria developed for clinical trials
has not been evaluated.
Magnetic resonance (MR) imaging may not pro-
vide a significant advantage over CT imaging in rou-
tine staging 30, but it may be of value in individuals
who are being considered for radical surgery 31. Of
particular benefit is the ability of MR imaging to assess
the extent of involvement of mediastinal structures such
as the heart (using cardiac-gated sequences), the chest
wall, and the diaphragm. Involvement of those struc-
tures has implications with respect to surgical ap-
proaches and resectability.
Studies involving positron-emission tomography
(PET) have demonstrated that mesothelioma is fluoro-
deoxyglucose (FDG)–avid 32. However, a role for PET
imaging in routine assessment has not been clearly
defined. Its limited spatial resolution requires integra-
tion with CT imaging to accurately localize areas of
FDG-uptake 33. In addition, PET imaging is not reliable
in identifying the local extent of tumour and mediasti-
nal lymph node involvement, and the latter can be con-
fused with nodular pleural thickening adjacent to the
mediastinum 34. Currently, the main use for PET
imaging would seem to be to exclude radical surgery
for patients with more extensive disease than is appar-
ent with conventional diagnostic imaging 35,36. Other
potential uses are in directing biopsy of FDG-avid tu-
mour sites and in re-staging after treatment.
2.3 Radical Surgery: Extrapleural Pneumonectomy
and Pleurectomy
The role of radical surgery in the management of
MPM is a topic of longstanding debate 37. The risks
of perioperative morbidity and mortality are signifi-
cant, and they depend greatly on the experience of
the surgical team.
Extrapleural pneumonectomy (EPP) entails extra-
pleural dissection and en bloc resection of the pleura
and lung, and resection and reconstruction of the peri-
cardium and diaphragm. Reported mortality rates haveCANADIAN PERSPECTIVE ON MALIGNANT MESOTHELIOMA
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been as high as 31% 38, although contemporary fig-
ures for high-volume centres are 3%–5% 39,40. Post-
operative morbidity is more than 50%. Atrial fibril-
lation is most common, but other serious complica-
tions include thromboembolism and acute respiratory
distress syndrome.
Pleurectomy involves debulking of the tumour and
preservation of the lung. The diaphragm and pericar-
dium are resected as needed. The risk of complica-
tions is not as significant as with EPP, mortality rates
being 1%–2% 39,41.
The survival benefits with radical surgery rely on
several factors. The extent to which tumour is debulked
is a strong predictor of survival 42,43, as is mediastinal
lymph node involvement 44,45.
An assessment of the effect of patient selection on
long-term outcomes is not possible 46. Typical candi-
dates for radical surgery have a good performance sta-
tus, adequate cardiac and pulmonary reserves, and
normal hepatic and renal function. Preoperative stag-
ing is rigorous, and aside from CT, MR, and PET imaging,
mediastinoscopy and laparoscopy are often performed
to exclude mediastinal lymph node involvement and
extension of disease through the diaphragm 47.
Gauging the effects of induction or adjuvant therapy
on survival from published reports is also difficult. There
is little expectation that surgery will result in clear re-
section margins, and locoregional recurrence is a prob-
lem with pleurectomy in particular 48. Even with what
might be viewed as optimal local disease management,
EPP followed by hemithorax radiation, the risk of dis-
tant relapse is high 49. There is consensus that, if radical
surgery is performed, chemotherapy and radical radia-
tion are necessary to deal with macroscopic and micro-
scopic residual disease.
2.4 Radiotherapy
There is a limited role for radiotherapy in management
of MPM. Palliation of symptomatic chest wall disease
is probably the most common indication for radio-
therapy; a variety of doses and dose schedules have
been reported to achieve pain relief 50.
Prophylactic radiotherapy to sites of chest-wall
instrumentation is of less clear benefit. Although mes-
othelioma has a tendency to track along biopsy and
chest-tube tracts, the frequency with which such spread
occurs is highly variable; it may depend on the extent
of the intervention 51. Reports conflict as to the effec-
tiveness of prophylactic radiotherapy 52–54, which is
reflected in guidelines both for 55,56 and against 11 its
routine prescription.
With a high expectation of residual disease fol-
lowing radical surgery, many practitioners feel that,
to improve local disease control rates, hemithorax ra-
diation is a necessary component of any combined-
modality therapy program. Although the merits of radi-
cal surgery are under debate, optimization of radiation
doses and application of newer techniques such as
intensity-modulated radiotherapy to reduce the risk of
local recurrence are attracting interest 57,58. Radiation
treatment fields following radical surgery are reason-
ably well defined by the limits of the resection, but
close collaboration with thoracic surgery is necessary
to ensure appropriate marking of visible residual dis-
ease, the reconstructed diaphragm, and anteromedial
pleural reflection. Rigorous definition of the clinical
target volume and avoidance of the remaining lung is
crucial in minimizing the complications seen with post-
operative radiation 59.
2.5 Systemic Therapy
Most chemotherapy drugs have limited activity against
MPM when tested as single agents 60. However, a land-
mark study comparing cisplatin plus pemetrexed with
cisplatin alone demonstrated a survival advantage for
the two-drug regimen 61. Comparable results were
seen in a trial of cisplatin plus raltitrexed versus cis-
platin 62. As a result, platinum-based chemotherapy
is now considered a standard of care in the manage-
ment of individuals with advanced MPM 9,63. How-
ever, the survival benefit with combination chemo-
therapy is modest, and interest in evaluating new drugs
in MPM remains.
Ranpirnase is a ribonuclease with some activity in
MPM 64, but the results of a randomized trial combin-
ing ranpirnase with chemotherapy are pending. Oral
tyrosine kinase inhibitors of epidermal growth factor
receptor 65,66 and platelet-derived growth factor recep-
tor 67 have not demonstrated significant activity in MPM,
but a monoclonal antibody against the platelet-derived
growth factor receptor may be promising 68. Studies of
drugs targeting vascular endothelial growth factor and
its receptor have so far proven disappointing 69,70, but
trials that focus on that pathway are still ongoing, in-
cluding a phase II trial of the oral tyrosine kinase
inhibitor sunitinib, sponsored by the NCIC CTG 71. Two
other agents of interest currently undergoing evalua-
tion in large clinical trials are inhibitors of proteaso-
mes 72 and histone deacetylase 73.
2.6 Prognostic Factors
Stage and prognostic index scores are both of interest
in clinical trials, but they have somewhat variable roles
in routine clinical practice.
TABLE I Immunohistochemical markers of epithelioid mesothelioma
Positive Negative
Calretinin  TTF-1
 CK5/6 CEA
 WT-1 BerEP4
D2-40 CD15
B72.3LEE et al.
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2.6.1 Staging
A variety of staging systems have been developed based
primarily on surgical series; these address the re-
sectability of MPM 38,74. Factors such as the extent of
pleural involvement and regional lymph node meta-
stasis are common features associated with survival.
However, as a practical matter, complete staging de-
pends on findings at surgery, which many patients do
not undergo.
The staging system proposed by the International
Mesothelioma Interest Group is generally employed
at the present time 75, and CT or MR imaging findings
(or both) are used as reasonable approximations for
absent surgical data.
2.6.2 Prognostic Indices
Perhaps of equal value are the prognostic indices that
have been derived using data from trials performed
by the European Organisation for Research and Treat-
ment of Cancer (EORTC) and Cancer and Leukemia
Group B 76,77. Both indices have been independently
validated in other series 78,79, and stratification is
based on combinations of biometric data. The EORTC
index places patients only into good-prognosis and
poor-prognosis categories, but that index is easier to
calculate than is the Cancer and Leukemia Group B
index, which identifies six prognostic groups. Inter-
estingly, neither index depends on stage, despite
Butchart staging information having been included in
the initial data analyses.
2.7 Outcome Measures
2.7.1 Quality of Life
Overall survival is the primary outcome of interest for
clinicians treating MPM, but relieving disease-related
symptoms and improving quality of life are also viewed
as important endpoints in the evaluation of new thera-
pies and interventions 80.
The randomized trials of cisplatin combined with
pemetrexed and raltitrexed demonstrated improve-
ments in quality of life, which was assessed using
standardized instruments 81,82. The pemetrexed trial
used a modified version of the Lung Cancer Symp-
tom Scale (LCSS), dubbed the LCSS-Meso, which un-
derwent formal validation in patients with MPM 83,84.
The raltitrexed trial used the EORTC core quality of
life questionnaire, the EORTC QLQ-C30 85, and the
lung cancer module, the EORTC QLQ–LC13 86, based
in part on the general applicability of the instruments
to individuals with advanced malignancies and the
commonality of symptoms affecting those with MPM
and lung cancer. Another study had demonstrated the
validity of the EORTC instruments in a small cohort of
patients with MPM 87.
2.7.2 Pulmonary Function
Malignant pleural mesothelioma causes a restrictive
ventilatory defect 88, classically demonstrated by a
markedly diminished total lung capacity with a normal
ratio of forced expiratory volume to vital capacity on
pulmonary function testing 89.
Response of MPM to treatment is associated with
significant improvements in forced expiratory volume
and vital capacity, and pulmonary function correlates
with the bulk of disease 27,90,91.
2.7.3 Circulating Tumour Markers
Soluble mesothelin-related proteins (SMRPs) include
mesothelin, megakaryocyte potentiating factor, and any
other related soluble molecules that are bound by the
monoclonal antibody OV569 92. Levels of SMRPs are
notably elevated in serum samples from individuals with
MPM, appear to be correlated with the bulk of disease,
and may be a useful prognostic marker 21,93,94. How-
ever, these relationships may hold true only in individu-
als with epithelioid, and not sarcomatoid, mesothelioma.
Serum osteopontin levels are also high in individu-
als with MPM and may be useful in diagnosing the dis-
ease in at-risk populations 22. Osteopontin levels are
prognostic, but as compared with levels of SMRPs, their
specificity is limited 93,95.
Levels of SMRPs fall after surgery for MPM 21, but
the data are currently insufficient to recommend rou-
tine use of either SMRPs or osteopontin in monitoring
response of MPM to treatment.
2.8 Clinical Research Directions: National Strategy
The Symposium on Malignant Mesothelioma: Cana-
dian Perspective and Research Directions was held
in March 2007 and was attended by 52 physicians and
researchers from across the country. The specialties
represented included thoracic surgery, pathology, ra-
diology, radiation oncology, and medical oncology.
After presentations on the diagnosis and management
of MPM, the attendees took part in an open discussion
on issues related to the development of a national re-
search strategy.
The frequency of MPM and the availability of spe-
cialist resources across the country place some limita-
tions on the scope of clinical research. A large ran-
domized controlled trial to evaluate the role of a novel
therapy or intervention cannot reasonably be performed
within Canada alone; international collaboration is re-
quired. In particular, the surgical expertise capable of
carrying out a trial of combined-modality therapy is
restricted to a handful of centres across the country.
With the uncertainties and biases related to radical sur-
gery among thoracic surgeons, performance of a trial
with randomization to a particular surgical procedure
is not considered practicable.
Similarly, questions related to hemithorax radia-
tion are relevant only to the small number of centres
with experience in delivering combined-modality
therapy. Although the value of prophylactic radiotherapy
to sites of chest wall instrumentation is somewhat con-
troversial, and few, if any, restrictions would affectCANADIAN PERSPECTIVE ON MALIGNANT MESOTHELIOMA
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the ability of centres to participate, performing another
trial to try to resolve this issue is considered low-
priority. Other concepts for trials of radiotherapy were
not put forward.
Continued work in the area of new drug develop-
ment received strong support. The recent opening of
the phase II trial of sunitinib has demonstrated the fea-
sibility of, and interest in, performing such studies. The
impetus to develop and evaluate novel targeted anti-
cancer agents is as relevant to MPM as it is to other
malignancies, and mechanisms such as the NCIC CTG
exist for carrying out such work in Canada.
To facilitate clinical trials, standardization of di-
agnostic and functional imaging procedures for stag-
ing is recommended (see Table II). Routine clinical
data collection to include information to calculate
prognostic index scores was also advised.
In evaluating the effects of new treatments and
interventions, overall survival and quality of life were
felt to be the most important outcome measures. As-
sessment of tumour response with serial CT imaging
using the modified response criteria developed for
MPM was advocated. Because of a strong correlation
with tumour response, incorporation of pulmonary
function testing as a trial endpoint was not considered
necessary unless a specific question regarding lung
function arises.
With the typical requirement for tissue biopsy speci-
mens to diagnose MPM, there was considerable sup-
port for correlative tissue studies to advance under-
standing of the biology of mesothelioma. Development
of a national mesothelioma tissue registry was recom-
mended, with links to Canadian expertise in genomics
and proteomics.
Areas of research that were not discussed were
ideas for studies of screening at-risk populations and
early detection, development of novel imaging
modalities, and general issues of palliative and sup-
portive care. A second symposium in 2–3 years is war-
ranted to tackle those issues and to review the progress
that will have been made in the intervening period.
3. CONCLUSIONS
With the expectation that the incidence of MPM will
remain unchanged—if not increase—over the next
decade, a national research strategy is needed. Ques-
tions regarding combined-modality therapy can be
addressed only at centres with appropriate surgical
and radiation oncology expertise, and those questions
will tend to focus on institutional experiences. Aside
from continuing to engage in new drug development,
efforts will be made to establish a national mesothe-
lioma tissue registry to support basic and clinical re-
search. Study of other issues related to screening,
diagnosis, and overall patient care requires further
discussion involving researchers and health care pro-
fessionals, as well as patients with MPM and their
families.
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